Business Context and Reporting Period
This Form 6-K filing covers the month of July 2011 for Prana Biotechnology Limited (ASX: PBT), an Australian biotechnology company. The registrant is a foreign private issuer filing under Rule 13a-16. The document serves as a Substantial Shareholder Notice under Section 708A(5) of the Corporations Act regarding share issuances.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific equity issuance event:
- Shares Issued: 5,694,580 Ordinary Fully Paid Shares at AUD$0.225 per share.
- Additional Shares: 300,000 Ordinary Fully Paid Shares issued at AUD$Nil.
- Total Issuance Date: June 30, 2011.
Material Changes
The primary material change reported is the issuance of approximately 5.99 million new ordinary shares on June 30, 2011. This issuance occurred without prior disclosure to investors under Part 6D.2 of the Corporations Act. The company intends to apply to the Australian Stock Exchange for quotation of these newly issued shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the regulatory requirement to disclose the share issuance. The company confirms compliance with Chapter 2M and Section 674 of the Corporations Act as of the notice date.
Investor Verification Checklist
- Verify the total number of shares issued (5,994,580) and the dilution impact on existing shareholders.
- Confirm the status of the ASX quotation application for the newly issued shares.
- Review the underlying agreement or reason for the issuance of 300,000 shares at a nil price.
- Check subsequent filings for the actual listing date of these shares on the ASX.